Key highlights
- Argent BioPharma shares traded at $0.020 at 11:04 AM AEDT on 19 November 2026, up 11.11%, while the S&P/ASX 200 was up 0.83% around midday.
- The company has entered a 10-year exclusive worldwide licence with Thai Phytomed International covering four cannabis genotypes.
- Argent will receive a 15% Royalty on profits from commercialisation of the licensed genetics.
Shares in Argent BioPharma Ltd (ASX:RGT) were trading at $0.020 during the session on 19 November 2026, up 11.11% at 11:04 AM AEDT, while the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. Argent BioPharma is a pharmaceutical development company focused on immune modulation and anti-inflammatory therapeutics, and it also holds legacy cannabis assets. In an announcement dated 27 October 2026, the company said it had entered a 10-year exclusive worldwide licensing agreement with Thai Phytomed International for four proprietary cannabis genotypes.
Scope of the Licence
Under the agreement, Thai Phytomed International receives exclusive worldwide rights to cultivate, process, extract, manufacture, market and sell products derived from the four genotypes, including flower, extracts and cannabinoid active pharmaceutical ingredients. The genotypes are MXC-THC-10/3, MXC-THC-81/5, MXC-THC-40/3 and MXC-THC-40/2. The licence runs for an initial 10 years and may be renewed for a further 10 years by written confirmation from both parties.
Ownership and Royalty Terms
The underlying genetics and intellectual property remain owned by Argent BioPharma (UK) Ltd, so the arrangement is a licence rather than a sale. Argent keeps the right to use the genetics for internal research and development. The company will receive a royalty of 15% of profits from commercialisation, calculated quarterly and covering sublicensing. Argent may terminate the licence if no commercial sale has been made within 24 months of delivery of the genetic material.
Sector Context
Cannabis-derived ingredients are regulated differently across markets, and commercialisation depends on approvals in each jurisdiction. Companies that hold genetics or intellectual property often license them to operators who fund regulatory and operational work, and royalty structures are used to share returns over the life of the agreement.
Risks Investors Are Watching
The royalty depends on profits generated by the licensee, and the licensee is responsible for obtaining approvals in each market. The agreement excludes the company's other pharmaceutical products, clinical dossiers and drug delivery technologies. Commercial sales must start within 24 months or the company can terminate, so the timing of royalty income is uncertain.
What to Watch Ahead
Investors will be looking at the first commercial sales under the licence, the quarterly royalty reporting and the progress of Argent's pharmaceutical development program, which the company says it will continue to focus its internal resources on.
About the Company
Argent BioPharma Ltd is an ASX-listed pharmaceutical development company. Its internal programs focus on immune modulation, anti-inflammatory therapeutics and other pharmaceutical products. Alongside those programs, the company has been working to extract value from its historical cannabis asset base through licensing arrangements. The licence with Thai Phytomed International does not cover the company's other pharmaceutical products, including CannEpil and CimetrA, nor its clinical dossiers, formulations or drug delivery technologies. The company says the licensing approach allows it to focus its internal scientific and financial resources on pharmaceutical development while still deriving income from non-core assets.
Session Context
The shares were trading at $0.020 during the session on 19 November 2026, up 11.11% at 11:04 AM AEDT. These are intraday figures rather than a closing price, so the move reflects trade in progress at that time. Over the same period the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. In the previous session on 18 November, the Dow Jones closed down 1.32% and the Nasdaq closed down 0.02%. Trading conditions can change quickly during a session, so later moves may differ from the figures shown here.
Closing Note
Argent shares rose in mid-morning trade on 19 November 2026. Commercial activity under the agreement will determine when royalties begin.






Please wait processing your request...